Susman Stephen, Santoso Breanna, Makary Mina S
Department of Radiology, Yale University Medical Center, New Haven, CT 06510, USA.
Heritage College of Osteopathic Medicine, Ohio University, Dublin, OH 43016, USA.
Biomedicines. 2024 Sep 30;12(10):2226. doi: 10.3390/biomedicines12102226.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide with an average five-year survival rate in the US of 19.6%. With the advent of HBV and HCV treatment and prevention, along with the rising rates of obesity, nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome are set to overtake infectious causes as the most common cause of HCC. While surgical resection and transplantation can be curative when amenable, the disease is most commonly unresectable on presentation, and other treatment approaches are the mainstay of therapy. In these patients, locoregional therapies have evolved as a vital tool in both palliation for advanced disease and as a bridge to surgical resection and transplantation. In this review, we will be exploring the primary locoregional therapies for HCC in patients with NAFLD, including transarterial chemoembolization (TACE), bland transarterial embolization (TAE), transarterial radioembolization (TARE), and percutaneous ablation.
肝细胞癌（HCC）是全球癌症相关死亡的第三大常见原因，在美国其平均五年生存率为19.6%。随着乙肝病毒（HBV）和丙肝病毒（HCV）治疗与预防措施的出现，以及肥胖率的上升，非酒精性脂肪性肝病（NAFLD）和代谢综合征将超过感染性病因，成为HCC最常见的病因。虽然手术切除和移植在合适的情况下可以治愈疾病，但该病在初诊时大多无法切除，其他治疗方法是主要的治疗手段。在这些患者中，局部区域治疗已发展成为晚期疾病姑息治疗以及手术切除和移植桥梁的重要工具。在本综述中，我们将探讨非酒精性脂肪性肝病患者肝细胞癌的主要局部区域治疗方法，包括经动脉化疗栓塞术（TACE）、单纯经动脉栓塞术（TAE）、经动脉放射性栓塞术（TARE）和经皮消融术。
